Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JS019 in Advanced Solid Tumors or Lymphomas
NCT05374226Phase 1Unknown
- Sponsor
- Suzhou Kebo Ruijun Biosciences
- Start
- Mar 2022
- Primary completion
- Dec 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of JS019 in solid tumor (advanced stage) and lymphoma (4 arms), sponsored by Suzhou Kebo Ruijun Biosciences. Primary endpoints: Safety and tolerability at 2 years and Maximum Tolerated Dose and Recommended Phase 2 Dose at 2 years. Status: unknown.
02
Drugs
JS019
03
Conditions
solid tumor (advanced stage)lymphoma
Beyond the preview
Go deeper on NCT05374226.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05374226.